Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome

Clinical and Experimental Gastroenterology

Volumn 6, Issue 1, 2013, Pages 123-128

  Chiba, Toshimi ^a   Yamamoto, Kazunari ^a   Sato, Shoko ^a   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Irritable bowel syndrome; Long term efficacy; Ramosetron; Safety

Indexed keywords

ALOSETRON; CILANSETRON; ONDANSETRON; PLACEBO; RAMOSETRON; SEROTONIN RECEPTOR;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADVERSE OUTCOME; ARTICLE; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HARD FECES; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; NONHUMAN; OUTCOME ASSESSMENT; PAIN THRESHOLD; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE;

EID: 84880794377     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S32721     Document Type: Article

References (41)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130: 1480-1491.
2. Grundy D, Al-Chaer ED, Aziz Q, et al. Fundamentals of neurogastroenterology: basic science. Gastroenterology. 2006;130: 1391-1411.
3. Okano S, Ikeura Y, Inatomi N. Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther. 2002;300:925-931.
4. Gully D, Geslin M, Serva L, et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2002;301:322-332.
5. Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J Pharmacol Sci. 2007;104: 263-273.
6. Ito H, Hidaka K, Miyata K, Kamato T, Nishida A, Honda K. Characterization of YMO60, a potent and selective 5-hydroxytryptamine 3 receptor antagonist, in rabbit nodose ganglion and NIE-115 neuroblastoma cells. J Pharmacol Exp Ther. 1992;263:1127-1132.
7. Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today. 2002;38:75-89.
8. Miyata K, Kamato T, Yamano M, et al. Serotonin (5-HT)3 receptor blocking activities of YMO60, a novel 4, 5, 6, 7-tetrahydrobenzimidazole derivative, and its enantiomer in anesthetized rats. J Pharmacol Exp Ther. 1991;259:815-819.
9. Färber L, Haus U, Späth M, Drechsler S. Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl. 2004; 119:2-8.
10. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol. 2004;141:1285-1293.
11. Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. Eur J Pharmacol. 2007;573:190-195.
12. Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology. 2007;15:5-9.
13. Mayer EA, Berman S, Derbyshire SW, et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther. 2002;16:1357-1366.
14. Siriwardena AK, Budhoo MR, Smith EP, Kellum JM. A 5-HT3 receptor agonist induces neutrally mediated chloride transport in rat distal colon. J Surg Res. 1993;55:55-59.
15. Hansen MB. The enteric nervous system III: a target for pharmacological treatment. Pharmacol Toxicol. 2003;93:1-13.
16. Miyata K, Kamato T, Nishida A, et al. Role of the serotonin3 receptor in stress-induced defecation. J Pharmacol Exp Ther. 1992;261: 297-303.
17. Kozlowski CM, Green A, Grundy D, Boissonade FM, Bountra C. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetized rat. Gut. 2000;46:474-480.
18. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97:S7-S26.
19. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035-1040.
20. Caras S, Krause G, Biesheuvel E, Steinborn C. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States study. Gastroenterology. 2001;120:A217.
21. Yamamoto C, Murakami H, Koyabu N, et al. Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the bloodbrain barrier. J Pharm Pharmacol. 2002;54: 1055-1063.
22. Hirata T, Keto Y, Nakata M, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil. 2008;20:557-565.
23. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1202-1211.
24. Ohta M, Suzuki T, Furuya T, et al. Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivatives. Chem Pharm Bull (Tokyo). 1996;44: 1707-1716.
25. Akuzawa S, lto H, Yamaguchi T. Comparative study of [3H] ramosetron and [3H] granisetron binding in the cloned human 5-hydroxytryptamine 3 receptors. Jpn J Pharmacol. 1998;78:381-384.
26. Yamano M, Kamato T, Nishida A, et al. Serotonin (5-HT)3 receptor antagonism of 4,5,6,7-tetra-hydrobenzimidazole derivatives against 5-HT-induced bradycardia in anesthetized rats. Jpn J Pharmacol. 1994;65:241-248.
27. Spiller R. Serotoninergic modulating drugs for functional gastrointestinal diseases. Br J Clin Pharmacol. 2002;54:11-20.
28. Fanselow MS, Helmstetter FJ. Conditional analgesia, defensive freezing, and benzodiazepines. Behav Neurosci. 1988;102:233-243.
29. Kameyama T, Nagasaka M, Yamada K. Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice. Neuropharmacology. 1985;24:285-290.
30. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion. 2008;77:225-235.
31. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100: 115-123.
32. Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23:1098-1104.
33. Matsueda K, Arakawa T, Matsumoto T, Sasaki D. Long-term study of YM060 (ramosetron hydrochloride) in Japanese patients (male) with diarrhea-predominant irritable bowel syndrome. Rinsho Iyaku. 2008;24:655-678. Japanese with English abstract.
34. Naliboff BD, Berman S, Chang L, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology. 2003;124:1738-1747.
35. Berman S, Munakata J, Naliboff BD, et al. Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain. 2000;4:157-172.
36. Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhea predominant irritable bowel syndrome in women. Gut. 2004;53: 1452-1458.
37. Camilleri M. Is there a SERT-ain association with IBS? Gut. 2004;53: 1396-1399.
38. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149-1159.
39. Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008;6:545-555.
40. Suh DC, Kahler KH, Choi IS, Shin H, Kralstein J, Shetzline M. Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis. Aliment Pharmacol Ther. 2007;25:681-692.
41. Spiller RC. Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome. Curr Opin Pharmacol. 2011;11:68-74